Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30131270 | 0.84 | CA12 (0.49) | KDM4EL3MBTL1CA12CA1CA2 | |
| SCHEMBL14398975 | 0.82 | ALDH1A1 (0.53) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL593088 | 0.79 | ALDH1A1 (0.51) | CA12CA1CA2CA9IDO1 | |
| SCHEMBL31549292 | 0.78 | CA12 (0.44) | KDM4EL3MBTL1CA12CA1CA2 | |
| SCHEMBL30102093 | 0.77 | PDK2 (0.44) | KDM4EL3MBTL1CA12CA1CA2 | |
| SCHEMBL13266333 | 0.76 | GAA (0.50) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL15756423 | 0.76 | CA12 (0.51) | KDM4EL3MBTL1CA12CA1CA2 | |
| SCHEMBL29420339 | 0.76 | CA12 (0.51) | KDM4EL3MBTL1CA12CA1CA2 | |
| SCHEMBL6989294 | 0.75 | CA12 (0.44) | KDM4EL3MBTL1CA12CA1CA2 | |
| SCHEMBL6991837 | 0.75 | KDM4E (0.45) | KDM4EL3MBTL1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240358842-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS | Stablix, Inc. | 2024-10-31 | — | — | US | disclosed |
| US-20240327411-A1 | SIRT6 ACTIVATORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-10-03 | — | — | US | disclosed |
| WO-2022272133-A2 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS | Stablix, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022272133-A2 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS | Stablix, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-2744775-B1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | UNIV EMORY (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9402850-B2 | BAX agonist, compositions, and methods related thereto | EMORY UNIVERSITY (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150250793-A1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-10 | — | — | US | disclosed |
| US-9040567-B2 | BAX agonist, compositions, and methods related thereto | EMORY UNIVERSITY (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140178374-A1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2013028543-A1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140178374-A1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | BAX, BID, BAD | KDM4E 3838/4885L3MBTL1 2411/4885CA12 3203/4885 |
| US-20240327411-A1 | SIRT6 ACTIVATORS | SIRT6, SIRT1, SIRT2 | KDM4E 1274/4885L3MBTL1 2178/4885CA12 4746/4885 |
| US-20150250793-A1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | BAX, ANXA1, BAD | KDM4E 2219/4885L3MBTL1 1001/4885CA12 3731/4885 |
| US-20240358842-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS | USP7, UBQLN1, UBQLN2 | KDM4E 1942/4885L3MBTL1 291/4885CA12 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.